Which of the following is not given for acute severe bronchial asthma: March 2011
**Core Concept**
Acute severe bronchial asthma requires immediate and effective management to prevent respiratory failure and other complications. The treatment involves a combination of medications that address bronchospasm, inflammation, and airway edema. The goal is to rapidly improve lung function and ensure adequate oxygenation.
**Why the Correct Answer is Right**
In acute severe bronchial asthma, intravenous magnesium sulfate is often administered to help relax bronchial smooth muscles, reduce airway resistance, and alleviate bronchospasm. Magnesium also has anti-inflammatory properties, which can help reduce airway edema. Additionally, magnesium can help regulate calcium channels, further contributing to bronchodilation. This makes intravenous magnesium sulfate a crucial component of acute asthma management.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is not specified, and without more information, it's difficult to determine its relevance to acute severe bronchial asthma management.
**Option B:** This option is incorrect because it is not typically given for acute severe bronchial asthma. While corticosteroids are essential for managing inflammation, this option does not specify the type or route of administration, making it an unclear choice.
**Option C:** This option is incorrect because beta-2 agonists (e.g., salbutamol) are commonly used as bronchodilators in acute asthma attacks, but they are usually administered via inhalation, not intravenously.
**Clinical Pearl / High-Yield Fact**
In acute severe bronchial asthma, the initial assessment should include vital signs, lung function tests (e.g., FEV1), and oxygen saturation. Administering high-flow oxygen and initiating bronchodilators promptly can significantly improve outcomes.
**Correct Answer: A.**